Simufilam – A Potential Game Changer in Alzheimer’s?
Cassava Sciences, Inc. (NASDAQ: SAVA), a clinical-stage company, announced that it has reached a consensus with the U.S. Food and Drug Administration (FDA), as to key elements of a crucial Phase 3 clinical program for Simufilam, its lead candidate for the treatment of Alzheimer’s. The...